Get access

Phenotypic assay of a hepatitis B virus strain carrying an rtS246T variant using a new strategy

Authors

  • Jie-li Hu,

    1. Institute for Viral Hepatitis, Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, China
    Search for more papers by this author
  • Jing Cui,

    1. Institute for Viral Hepatitis, Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, China
    Search for more papers by this author
  • Jin-jun Guo,

    1. Department of Gastroenterology and Hepatology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
    Search for more papers by this author
  • Wen-lu Zhang,

    1. Institute for Viral Hepatitis, Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, China
    Search for more papers by this author
  • Xue-fei Cai,

    1. Institute for Viral Hepatitis, Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, China
    Search for more papers by this author
  • Zuo-wei Yuan,

    1. Institute for Viral Hepatitis, Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, China
    Search for more papers by this author
  • Qing-ling Li,

    1. Department of Biochemistry and Molecular Biology, Fundamental Medical Institute, Chongqing Medical University, Chongqing, China
    Search for more papers by this author
  • Xiao-yan Deng,

    1. Institute for Viral Hepatitis, Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, China
    Search for more papers by this author
  • Ai-zhong Zeng,

    1. Department of Infectious Diseases, the First Affiliated Hospital, Chongqing Medical University, Chongqing, China
    Search for more papers by this author
  • Yuan Hu,

    1. Institute for Viral Hepatitis, Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, China
    Search for more papers by this author
  • Ni Tang,

    1. Institute for Viral Hepatitis, Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, China
    Search for more papers by this author
  • Ai-long Huang

    Corresponding author
    1. Institute for Viral Hepatitis, Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, China
    • Institute for Viral Hepatitis, Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing 400016, China.
    Search for more papers by this author

Abstract

Phenotypic assays of hepatitis B virus (HBV) play an important role in research related to the problem of drug resistance that emerges during long-term nucleot(s)ide therapy in patients with chronic hepatitis B. Most of the phenotypic assay systems that are available currently rely on the transfection of recombinant replication-competent HBV DNA into hepatoma cell lines. Cloning clinical HBV isolates using conventional digestion-and-ligation techniques to generate replication-competent recombinants can be very difficult because of the sequence heterogeneity and unique structure of the HBV genome. In this study, a new strategy for constructing an HBV 1.1× recombinant was developed. The core of this strategy is the “fragment substitution reaction” (FSR). FSR allows PCR fragments to be cloned without digestion or ligation, providing a new tool for cloning fragments or genomes amplified from serum HBV DNA, and therefore making the assay of HBV phenotypes more convenient. Using this strategy, a phenotypic assay was performed on an HBV strain carrying an rtS246T variant isolated from a patient with chronic hepatitis B that was only responsive partially to entecavir therapy. The results indicated that this strain is sensitive to entecavir in vitro. J. Med. Virol. 84:34–43, 2011. © 2011 Wiley Periodicals, Inc.

Ancillary